About this item:

37 Views | 15 Downloads

Author Notes:

Address for correspondence: Ann Marie Navar, MD, PhD; Duke Clinical Research Institute, 2400 Pratt St. #7521, Durham, NC, USA 27705; Tel: 919-668-8666; Fax: 919-668-7089; navar006@dm.duke.edu.

The authors would like to thank Erin Campbell, MS, for her editorial contributions to this manuscript. Ms. Campbell did not receive compensation for her assistance, apart from her employment at the institution where this study was conducted.

See publication for full list of disclosures.


Research Funding:

This study was supported by Sanofi Pharmaceuticals and Regeneron Pharmaceuticals.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Cardiac & Cardiovascular Systems
  • Cardiovascular System & Cardiology
  • cardiovascular disease
  • drug-related side effects and adverse reactions
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • nocebo effect

Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry

Show all authors Show less authors


Journal Title:

Circulation: Cardiovascular Quality and Outcomes


Volume 11, Number 3


, Pages e004249-e004249

Type of Work:

Article | Post-print: After Peer Review


When compared against placebo in randomized trials, statins are extremely well tolerated, causing muscle related side effects in 1% or fewer of treated patients.1 Yet in routine practice, patients often report having symptoms which are misattributed to their statin.2–4 Using data from the Patient and Provider Assessment of Lipid Management (PALM) Registry, we examined patient-reported rates of statin intolerance, characteristics of patients with perceived side effects, and response to perceived statin intolerance in contemporary practice.

Copyright information:

© 2018 American Heart Association, Inc.

Export to EndNote